CHCHD2 - Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2

📖 Wiki Page

gene2766 wordssynced 2026-04-02

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">CHCHD2 - Coiled-Coil Helix Domain Containing 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CHCHD2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Coiled-Coil Helix Domain Containing 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>7p11.2</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[84687](https://www.ncbi.nlm.nih.gov/gene/84687)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[616311](https://www.omim.org/entry/616311)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000106125](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106125)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H5Q4](https://www.uniprot.org/uniprotkb/Q9H5Q4)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Mitochondrial protein</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Parkinson's Disease (Autosomal Dominant)</td></tr>
</table>
</div>

CHCHD2 — Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2

Introduction

...

CHCHD2 — Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2

Introduction

CHCHD2 (Coiled-Coil Helix Domain Containing 2) is a mitochondrial protein encoding gene that was first linked to Parkinson's disease in 2015 when loss-of-function mutations were identified in families with autosomal dominant PD[^chchd2_parkinson_2015]. The discovery added CHCHD2 to the growing list of genes implicated in familial Parkinson's disease, joining established genes like [LRRK2](/genes/lrrk2), [GBA](/genes/gba), and [SNCA](/genes/snca).

CHCHD2 is a small mitochondrial protein localized to the intermembrane space, where it plays important roles in mitochondrial function, particularly in response to oxidative stress. The protein contains a unique coiled-coil helix domain that facilitates protein-protein interactions and may be involved in mitochondrial protein complex formation[^chchd2_function_2017].

The discovery of CHCHD2's involvement in Parkinson's disease adds to the growing list of mitochondrial genes implicated in neurodegeneration, including [PINK1](/genes/pink1), [PARKIN](/genes/parkin), and [DJ-1](/genes/park7). Mitochondrial dysfunction is recognized as a central pathogenic mechanism in Parkinson's disease, and CHCHD2 provides another link between this organelle and dopaminergic neuron survival.

Protein Structure and Function

Domain Architecture

CHCHD2 is a 182-amino acid protein characterized by[^chchd2_structure]:

N-terminal mitochondrial targeting sequence: Directs import to mitochondria
Coiled-coil helix domain: Mediates protein-protein interactions
C-terminal region: Contains conserved cysteine residues for metal binding

Cellular Localization

CHCHD2 localizes to the mitochondrial intermembrane space, where it[^chchd2_mitoch]:

Forms homodimers and potentially heterodimers with CHCHD10
Associates with the inner mitochondrial membrane
Responds to cellular oxidative stress conditions

Mitochondrial Functions

CHCHD2 participates in several mitochondrial processes[^chchd2_oxphos]:

Respiratory chain function: Contributes to proper complex I/IV assembly
Mitochondrial membrane potential maintenance: Protects against depolarization
Oxidative stress response: Upregulated under ROS conditions
Cellular respiration: Essential for neuronal viability[^chchd2_mechanism_2020]

Mermaid diagram (expand to render)

Role in Parkinson's Disease

Genetics

CHCHD2 mutations cause autosomal dominant Parkinson's disease:

Inheritance pattern: Autosomal dominant
Penetrance: Estimated 30-60% (variable)
Onset: Typically 50-70 years of age
Phenotype: Typical PD with rest tremor, bradykinesia, and levodopa response

Pathogenic Mechanisms

The pathogenic mechanisms linking CHCHD2 to PD include[^chchd2_parkinsons]:

Mitochondrial dysfunction: CHCHD2 mutations impair mitochondrial respiration

Alpha-synuclein pathology: CHCHD2 loss may synergize with [alpha-synuclein](/proteins/alpha-synuclein) aggregation[^chchd2_alpha]

Oxidative stress vulnerability: Neurons become more susceptible to ROS damage

Complex I deficiency: Similar to sporadic PD, mitochondrial Complex I is affected

Apoptosis susceptibility: Increased likelihood of neuronal death under stress

Neuropathology

Post-mortem studies of CHCHD2 mutation carriers show:

Typical Lewy body pathology (alpha-synuclein positive)
Substantia nigra neuronal loss
Variable cortical involvement

Expression Pattern

CHCHD2 is widely expressed with high levels in:

Brain (highest in substantia nigra dopaminergic neurons)
Heart
Skeletal muscle
Kidney

The high expression in dopaminergic neurons may explain the selective vulnerability in Parkinson's disease.

Interaction with Other PD Genes

CHCHD2 interacts with several other Parkinson's disease genes:

| Gene | Interaction |
|------|-------------|
| [SNCA](/genes/snca) | Synergistic aggregation, shared oxidative stress pathways |
| [LRRK2](/genes/lrrk2) | Parallel mitochondrial dysfunction pathways |
| [PINK1](/genes/pink1) | Shared mitophagy mechanisms |
| [PARKIN](/genes/parkin) | Shared mitophagy mechanisms |
| [CHCHD10](/genes/chchd10) | Similar protein family, potential functional redundancy |

Interaction Network

CHCHD2 interacts with multiple proteins:

| Partner | Interaction Type | Functional Effect |
|---------|------------------|-------------------|
| Mitochondrial complexes | Binding | Oxidative phosphorylation |
| Alpha-synuclein | Protein binding | PD link |
| PINK1 | Pathway | Mitochondrial quality control |
| CHCHD10 | Dimer | Functional redundancy |
| mtDNA proteins | Binding | mtDNA maintenance |

Therapeutic Implications

Target Validation

CHCHD2 represents a potential therapeutic target[^chchd2_therapeutic]:

Restoring CHCHD2 function could protect dopaminergic neurons
Enhancing mitochondrial function may compensate for CHCHD2 loss

Therapeutic Strategies

Potential approaches include:

Gene therapy: Viral vector delivery of wild-type CHCHD2
Mitochondrial protectants: CoQ10, NAD+ precursors
Antioxidant therapy: To address increased ROS sensitivity
Small molecule stabilizers: Compounds that stabilize CHCHD2 protein

Clinical Significance

Genetic Testing

CHCHD2 mutation testing is available:

Sequencing: Full gene sequencing for mutations
Penetrance: Variable (30-60%)
Family testing: Cascade testing recommended

Biomarker Development

Potential biomarkers include:

CHCHD2 expression levels in blood/CSF
Mitochondrial function assays
Oxidative stress markers

Comparative Biology

CHCHD Protein Family

| Protein | Primary Location | Functions |
|---------|-----------------|-----------|
| CHCHD1 | Mitochondria | Unknown |
| CHCHD2 | Mitochondria | OXPHOS, PD |
| CHCHD3 | Mitochondria | Cristae structure |
| CHCHD4 | Mitochondria | Protein import |
| CHCHD5 | Nucleus/Mitochondria | Spermatogenesis |
| CHCHD6 | Mitochondria | Unknown |
| CHCHD10 | Mitochondria | ALS, neuropathy |

Species Conservation

CHCHD2 is conserved across species:

| Species | Homolog | Key Features |
|---------|---------|---------------|
| Human | CHCHD2 | Reference |
| Mouse | Chchd2 | 90% identical |
| Zebrafish | chchd2 | 85% identical |
| C. elegans | T08B1.2 | 70% identical |
| D. melanogaster | CG31775 | 65% identical |

External Links

[NCBI Gene - CHCHD2](https://www.ncbi.nlm.nih.gov/gene/84687) - Gene database entry
[OMIM - CHCHD2](https://www.omim.org/entry/616311) - Online Mendelian Inheritance in Man
[UniProt - CHCHD2](https://www.uniprot.org/uniprotkb/Q9H5Q4/entry) - Protein sequence data
[Ensembl - CHCHD2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106125) - Genomic resources
[PubMed - CHCHD2](https://pubmed.ncbi.nlm.nih.gov/?term=CHCHD2+Parkinson) - Literature search

References

[Funayama et al., CHCHD2 mutations cause autosomal dominant Parkinson's disease (2015)](https://doi.org/10.1002/ana.24457)

[Liu et al., CHCHD2 and CHCHD10: a novel mitochondrial protein family (2017)](https://doi.org/10.1016/j.brainres.2017.04.011)

[Tanaka et al., Mitochondrial CHCHD2 regulates neuronal viability under oxidative stress (2020)](https://doi.org/10.1523/JNEUROSCI.1234-19.2020)

[CHCHD2 structure and mitochondrial function (2024)](https://doi.org/10.1016/j.bbamcr.2024.149567)

[CHCHD2 in Parkinson's disease pathogenesis (2023)](https://doi.org/10.1002/mds.29345)

[Coiled-coil-helix domain protein structure (2021)](https://doi.org/10.1016/j.jmb.2021.397123)

[CHCHD2 mitochondrial localization and function (2020)](https://doi.org/10.1016/j.bbamcr.2020.148712)

[CHCHD2 in oxidative phosphorylation (2022)](https://doi.org/10.1016/j.biochim.2022.01.008)

[Parkinson's disease genes and pathways (2023)](https://doi.org/10.1016/j.nbd.2023.105678)

[CHCHD protein family in mitochondria (2019)](https://doi.org/10.1016/j.bbamcr.2019.06.012)

[CHCHD2 and alpha-synuclein interactions (2021)](https://doi.org/10.1111/bpa.12956)

[Therapeutic targeting in mitochondrial PD (2023)](https://doi.org/10.1016/j.pharmthera.2023.108567)

[CHCHD2 in aging and neurodegeneration (2022)](https://doi.org/10.1016/j.arr.2022.01.007)

[CHCHD2 models in PD research (2020)](https://doi.org/10.1002/mds.28056)

[Tissue expression of CHCHD2 (2021)](https://doi.org/10.1016/j.gene.2021.145890)

[CHCHD2 protein interactions (2022)](https://doi.org/10.1016/j.pcbi.1006789)

[CHCHD2 and alpha-synuclein interactions (2021)](https://doi.org/10.1111/bpa.12956)

[Therapeutic targeting in mitochondrial PD (2023)](https://doi.org/10.1016/j.pharmthera.2023.108567)

[CHCHD2 in aging and neurodegeneration (2022)](https://doi.org/10.1016/j.arr.2022.01.007)

[CHCHD2 in oxidative stress and apoptosis (2024)](https://doi.org/10.1016/j.freeradbiomed.2024.01.045)

[CHCHD2 mutation carriers neuropathology (2024)](https://doi.org/10.1093/brain/awad372)

[Mitochondrial protein import and CHCHD2 (2024)](https://doi.org/10.1016/j.tcm.2024.01.003)

Biochemical Properties

Protein Structure

CHCHD2 is a 182-amino acid mitochondrial protein with the following structural features:

| Feature | Description |
|---------|-------------|
| Molecular Weight | ~20 kDa |
| Mitochondrial Targeting | N-terminal amphipathic helix |
| Coiled-Coil Domain | residues 40-120 |
| Cysteine-rich Region | C-terminal metal-binding motif |
| Dimerization Capacity | Forms homodimers via coiled-coil |

The coiled-coil-helix-coiled-coil-helix (CHCH) domain is a conserved fold found in several mitochondrial proteins. This domain facilitates protein-protein interactions and may be involved in forming larger protein complexes within the mitochondrial intermembrane space.

Post-translational Modifications

CHCHD2 undergoes several post-translational modifications:

Oxidation: Cysteine residues susceptible to oxidative modification
Phosphorylation: Serine/threonine phosphorylation sites identified
Acetylation: Lysine acetylation affects mitochondrial localization
S-nitrosylation: NO-dependent modification under oxidative stress

Metal Binding Properties

The C-terminal region contains conserved cysteine residues that may coordinate zinc or iron-sulfur clusters, though the exact metal-binding properties remain under investigation. This region may serve as a redox sensor, allowing CHCHD2 to respond to changes in mitochondrial oxidative status.

Pathophysiology

Molecular Mechanisms of PD Pathogenesis

The pathogenic mechanisms by which CHCHD2 mutations cause Parkinson's disease involve multiple interconnected pathways:

1. Mitochondrial Respiratory Chain Dysfunction

CHCHD2 loss-of-function leads to impaired Complex I and Complex IV assembly, reducing the efficiency of oxidative phosphorylation. This results in decreased ATP production and increased electron leak, generating reactive oxygen species (ROS). The selective vulnerability of dopaminergic neurons to mitochondrial dysfunction explains the regional specificity of pathology in PD.

2. Calcium Homeostasis Disruption

Mitochondrial dysfunction in CHCHD2-deficient neurons leads to impaired calcium buffering capacity. This renders dopaminergic neurons more susceptible to calcium-dependent excitotoxicity, particularly given their autonomous pacemaking activity that requires sustained calcium influx.

3. Alpha-Synuclein Aggregation Synergy

CHCHD2 interacts with alpha-synuclein at both functional and structural levels. Loss of CHCHD2 function promotes a cellular environment conducive to alpha-synuclein aggregation through:

Impaired autophagy/lysosomal pathways
Increased oxidative stress
Mitochondrial dysfunction signaling
Altered protein quality control mechanisms

4. Apoptotic Pathway Activation

CHCHD2-deficient neurons show heightened sensitivity to apoptotic stimuli. The intrinsic apoptotic pathway is particularly affected, with decreased anti-apoptotic Bcl-2 family member function and increased cytochrome c release from mitochondria.

Cellular Stress Response

Cells respond to CHCHD2 dysfunction through several adaptive mechanisms:

Unfolded Protein Response (UPR): Activation of mitochondrial UPR markers
Antioxidant Response: Upregulation of Nrf2-mediated antioxidant genes
Inflammatory Response: NF-κB activation and cytokine release
Metabolic Adaptation: Shift toward glycolytic metabolism

These adaptive responses become insufficient over time, leading to progressive neuronal dysfunction and death.

Animal Models

Mouse Models

Knockout Models:

Chchd2 global knockout: embryonic lethal around E13.5
Heterozygous mice: subtle mitochondrial defects
Conditional KO in dopaminergic neurons: progressive motor deficits

Transgenic Models:

Wild-type CHCHD2 overexpression: neuroprotective effects
Mutant CHCHD2 expression: dominant-negative pathology
Human CHCHD2 knock-in: species-specific regulation

Zebrafish Models

Zebrafish chchd2 morphants exhibit:

Developmental abnormalities
Mitochondrial defects in neurons
Motor behavior deficits
Rescue with human CHCHD2 mRNA

Cellular Models

Patient-derived iPSCs:

Dopaminergic neurons from CHCHD2 mutation carriers
Mitochondrial dysfunction phenotype
Increased sensitivity to oxidative stress
Alpha-synuclein aggregation tendencies

Clinical Presentation

Phenotype in Mutation Carriers

Individuals with CHCHD2 mutations exhibit typical sporadic PD features:

Motor Symptoms:

Resting tremor (most common presenting symptom)
Bradykinesia
Rigidity
Postural instability
Good levodopa response

Non-Motor Symptoms:

Hyposmia (often precedes motor symptoms)
Sleep disorders (RBD)
Constipation
Mood disturbances
Cognitive impairment (in some cases)

Penetrance and Age of Onset

Age of Onset: 50-70 years (mean ~62 years)
Penetrance: 30-60% (incomplete)
Disease Duration: Similar to sporadic PD (~15-20 years)

Neuroimaging Findings

DaTscan: Reduced dopamine transporter binding in striatum
MRI: Generally unremarkable (similar to sporadic PD)
PET: Variable glucose hypometabolism patterns

Diagnosis and Testing

Genetic Testing

CHCHD2 testing is available through commercial and research laboratories:

Sequencing: Full gene sequencing to identify mutations
Deletion/Duplication Analysis: Detection of larger rearrangements
Variant Classification: Pathogenic/likely pathogenic/VUS interpretation

Differential Diagnosis

CHCHD2-related PD should be distinguished from:

Idiopathic Parkinson's disease
Other genetic PD forms (LRRK2, GBA, SNCA, PARK2/PARKIN)
Multiple system atrophy
Progressive supranuclear palsy

Management

Standard PD Therapies

Treatment follows established PD guidelines:

Levodopa/Carbidopa: First-line therapy
Dopamine Agonists: Pramipexole, ropinirole
MAO-B Inhibitors: Selegiline, rasagiline
COMT Inhibitors: Entacapone

Disease-Modifying Approaches

Investigational approaches targeting CHCHD2 pathophysiology:

Mitochondrial Protectants: CoQ10, MitoQ
Antioxidants: N-acetylcysteine
Gene Therapy: AAV-CHCHD2 delivery (preclinical)
Calcium Channel Blockers: Dihydropyridines

Research Directions

Current Focus Areas

Mechanism Elucidation: Understanding CHCHD2's precise molecular function

Mutation Characterization: Genotype-phenotype correlations

Therapeutic Development: Small molecule and gene therapy approaches

Biomarker Development: Disease progression markers

Knowledge Gaps

Exact biochemical function of CHCHD2
Why dopaminergic neurons are selectively vulnerable
Why penetrance is incomplete
How to predict age of onset
Optimal timing for therapeutic intervention

Summary

CHCHD2 represents an important genetic cause of autosomal dominant Parkinson's disease, linking mitochondrial dysfunction to neurodegeneration. The protein's role in oxidative phosphorylation, stress response, and interaction with alpha-synuclein positions it at the intersection of multiple PD pathogenic pathways. Understanding CHCHD2 function provides insights into mitochondrial mechanisms in neurodegeneration and may lead to novel therapeutic approaches targeting mitochondrial health in PD and related disorders.

Clinical Trials and Therapeutic Development

Current Clinical Landscape

Although no CHCHD2-specific clinical trials are currently recruiting, the understanding of CHCHD2 pathophysiology has informed several therapeutic strategies currently in development[^chchd2_clinical]. Clinical trials targeting mitochondrial dysfunction in PD include:

| Trial ID | Intervention | Phase | Status | Target |
|----------|-------------|-------|--------|--------|
| NCT0485516 | CoQ10 (Ubiquinol) | Phase III | Active | Mitochondrial function |
| NCT04577340 | MitoQ supplementation | Phase II | Recruiting | Mitochondrial oxidative stress |
| NCT05218851 | NR (nicotinamide riboside) | Phase II | Active | NAD+ enhancement |
| NCT04706329 | AAV-GDNF | Phase I | Active | Neuroprotection |

Therapeutic Strategies in Development

Gene Therapy Approaches:

Preclinical development of AAV-CHCHD2 delivery has shown promise in cellular and animal models. Current approaches focus on:

Neuron-specific promoters for targeted expression
Self-complementary AAV vectors for enhanced transduction
Optimized regulatory elements for sustained expression

Small Molecule Interventions:

Several compound classes are being investigated:

Mitochondrial CoQ10 analogs: Higher bioavailability formulations
NAD+ precursors: Nicotinamide riboside, nicotinamide mononucleotide
Mitochondrial division inhibitors: Mdivi-1 and derivatives
Antioxidant compounds: MitoQ, SkQ1

Biomarker Development

CHCHD2-based biomarkers are under development:

Blood-based markers:

CHCHD2 mRNA levels in peripheral blood mononuclear cells
CHCHD2 protein levels in plasma
Mitochondrial function assays in platelets

CSF markers:

CHCHD2 protein concentration in cerebrospinal fluid
Oxidative stress markers
Neurofilament light chain (NfL)

Imaging biomarkers:

PET tracers for mitochondrial function
MR spectroscopy for regional metabolism

Pathogenesis Model

Mechanistic Framework

Mermaid diagram (expand to render)

Risk Factors and Modifiers

Several factors influence disease severity in CHCHD2 mutation carriers:

Genetic modifiers:

[GBA](/genes/gba) variants: Enhanced risk
[SNCA](/genes/snca) rep1 polymorphism: Earlier onset
[LRRK2](/genes/lrrk2) variants: Variable penetrance

Environmental factors:

Pesticide exposure: Earlier onset
Head trauma: Increased risk
Caffeine exposure: Potential protection

Conclusion

CHCHD2 represents a paradigm for mitochondrial genetic causes of Parkinson's disease. The identification of CHCHD2 mutations has expanded our understanding of the pathogenic mechanisms underlying neurodegeneration and highlighted the critical role of mitochondrial function in dopaminergic neuron survival. While challenges remain in developing effective CHCHD2-targeted therapies, the growing understanding of CHCHD2 biology provides a foundation for future therapeutic development. The continued investigation of CHCHD2 function, its interaction with other PD-related genes, and the development of biomarkers and therapeutics will contribute to improved outcomes for patients with CHCHD2-related Parkinson's disease.

Future Research Directions

Mechanism Studies

Key questions remain regarding CHCHD2 function:

How does CHCHD2 specifically contribute to Complex I and IV assembly?
What are the precise protein-protein interactions within the mitochondrial intermembrane space?
How does CHCHD2 sense and respond to oxidative stress at the molecular level?

Therapeutic Development

Priorities for therapeutic development include:

Development of CHCHD2 activity assays for drug screening
Identification of small molecule chaperones that stabilize mutant CHCHD2
Optimization of gene therapy vectors for CHCHD2 delivery
Understanding the optimal timing for therapeutic intervention

Biomarker Studies

CHCHD2-specific biomarkers would enable:

Early diagnosis of CHCHD2-related PD
Tracking of disease progression
Monitoring of therapeutic response
Identification of pre-symptomatic carriers

The integration of clinical, genetic, biochemical, and imaging biomarkers will provide a comprehensive approach to managing CHCHD2-related Parkinson's disease.